Journal of Human Reproductive Sciences

ORIGINAL ARTICLE
Year
: 2015  |  Volume : 8  |  Issue : 1  |  Page : 25--29

Different gonadotropin releasing hormone agonist doses for the final oocyte maturation in high-responder patients undergoing in vitro fertilization/intra-cytoplasmic sperm injection


Emre Goksan Pabuccu1, Recai Pabuccu2, Gamze Sinem Caglar1, Banu Yilmaz1, Asli Yarci1 
1 Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Turkey
2 Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University; Centrum Clinic Women Healthcare and IVF Center, Ankara; Dogu Fertil IVF Center, Malatya, Turkey

Correspondence Address:
Emre Goksan Pabuccu
Nenehatun Street, No: 59, Gaziosmanpasa, Ankara
Turkey

Context: Efficacy of gonadotropin releasing hormone agonists (GnRH-a) for ovulation in high-responders. Aims: The aim of the current study is to compare the impact of different GnRH-a doses for the final oocyte maturation on cycle outcomes and ovarian hyperstimulation syndrome (OHSS) rates in high-responder patients undergoing ovarian stimulation. Settings And Designs: Electronic medical records of a private in vitro fertilization center, a retrospective analysis. Subjects and Methods: A total of 77 high-responder cases were detected receiving GnRH-a. Group I consisted of 38 patients who received 1 mg of agonist and Group II consisted of 39 patients who received 2 mg of agonist. Statistical Analysis: In order to compare groups, Student«SQ»s t-test, Mann-Whitney U-test, Pearson«SQ»s Chi-square test or Fisher«SQ»s exact test were used where appropriate. A P < 0.05 was considered as statistically significant. Result: Number of retrieved oocytes (17.5 vs. 15.0, P = 0.510), implantation rates (46% vs. 55.1%, P = 0.419) and clinical pregnancy rates (42.1% vs. 38.5%, P = 0.744) were similar among groups. There were no mild or severe OHSS cases detected in Group I. Only 1 mild OHSS case was detected in Group II. Conclusion: A volume of 1 or 2 mg leuprolide acetate yields similar outcomes when used for the final oocyte maturation in high-responder patients.


How to cite this article:
Pabuccu EG, Pabuccu R, Caglar GS, Yilmaz B, Yarci A. Different gonadotropin releasing hormone agonist doses for the final oocyte maturation in high-responder patients undergoing in vitro fertilization/intra-cytoplasmic sperm injection .J Hum Reprod Sci 2015;8:25-29


How to cite this URL:
Pabuccu EG, Pabuccu R, Caglar GS, Yilmaz B, Yarci A. Different gonadotropin releasing hormone agonist doses for the final oocyte maturation in high-responder patients undergoing in vitro fertilization/intra-cytoplasmic sperm injection . J Hum Reprod Sci [serial online] 2015 [cited 2020 Aug 9 ];8:25-29
Available from: http://www.jhrsonline.org/article.asp?issn=0974-1208;year=2015;volume=8;issue=1;spage=25;epage=29;aulast=Pabuccu;type=0